MGC Pharmaceuticals launches CannEpil® App to collect real-time data for medical practitioners

MGC Pharmaceuticals Ltd (ASX:MXC) (OTCMKTS:MGCLF) (FRA:H5O) has launched the CannEpil® App which gives medical professionals access to the International Library of Cannabinoids (ILC) as part of its collaboration with the Royal Melbourne Institute of Technology (RMIT). The new app is designed to collect patient data, whilst under the supervision of a medicinal practitioner, with the goal of further evaluating the usage, dosage and efficacy of CannEpil® as a treatment. It is a cross-platform application available to download from both the Apple App Store and Google Play Store. Shares have been as much as 9% higher in early trading to A$0.024 “Data access for doctors” MGC Pharma co-founder and managing director Roby Zomer said: “Data is extremely important in the healthcare industry and is something that is not widely collected or stored at this time within the medicinal cannabis sector. “The App and the ILC provides the medical community with access to what doctors need the most in order to start adopting and implementing phytocannabinoid treatments into their treatment toolkit: validated patient-based data, collected according to globally recognised standards, available for efficient comparative medical decision making and prescription. “The use of the data we collect in this way is designed to aid the phytocannabinoid industry as a whole and to fill the void where there has been a significant lack of knowledge and data, responsibly collected and maintained. “MXC believes this data will be invaluable for future product development, health and safety studies, and much more.” Strategic milestone The launch of the CannEpil® App as part the development of the ILC is a strategic milestone in the company’s progress as it strengthens its medicinal cannabis IP and allows MGC Pharma to remain at the forefront of cannabinoid development with its data. Data collection on this scale also represents a major step forward for the industry by providing transparent and comprehensive information on specific treatments, therapeutic benefits, wider implications and to advance and enhance the suites of products that are available to patients. The app will record patient responses to medical questionnaires and the treating practitioner will be able to view the responses in real-time. “Monitor treatment and dosing” The ILC has been developed as a world-first centralised platform compiling and curating the diverse range of existing data on the therapeutic benefits of cannabinoids. RMIT Associate Professor Nitin Mantri, who co-designed CannEpil® App and ILC, said that in this age of digital health and precision medicine, collecting patient data real-time allowed the doctors to monitor treatment and titer dosing as required. He said: “It also benefits industry to understand the various outcomes expected from the medicine and use this knowledge to further develop the products. “Whilst the CannEpil® app focuses on patient outcomes for a specific formulation, ILC collects data for all different types of cannabis strains and their efficacy for treating various disorders. “ILC when used by leading cannabis researchers and industries will gather evidence to demonstrate policymakers and community the various benefits of cannabis plant.” “Ahead of the curve” MGC Pharma clinical research officer Dr Nadya Lisovoder said: “The medical community around the world is expecting scientific-based data concerning the safety and efficacy of medical cannabis-based treatments. “In parallel with randomised clinical trials, which MGC Pharma is ahead of the curve in several indications, this active collection of medical data will support the personalisation of treatments, facilitate the R&D process and encourage dialogue with the medical community, which is crucial to developing viable products for the market. “This data will be comprised of the demographic profile of the patients, concomitant treatments and adverse events. “The efficacy data will be evaluated with tools which are validated by regulatory agencies and medical communities. “We believe that this will allow MGC Pharma to base future developments on a deeper understanding of the treatments being developed, and create better products for more patients, globally.”